Although the modulation of HIF-1 activity is a high-priority target for clinical therapies, our data accentuate the necessity of optimizing possible pharmacological inhibition of HIF-1 in therapeutic applications for the treatment of DN. The gene discussed is HIF1A; the disease is liver dysplastic nodule.